2007
DOI: 10.1016/j.ijrobp.2007.07.088
|View full text |Cite
|
Sign up to set email alerts
|

Radioimmunotherapy and Temozolomide in the Treatment of Glioblastoma Multiforme: A 20 Year Experience

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
6
0

Year Published

2019
2019
2019
2019

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(6 citation statements)
references
References 0 publications
0
6
0
Order By: Relevance
“…Two phase I trials with the EGFR-specific mAb nimotuzumab labeled with 188-Re have been published [18,101] and a median overall survival of 18.7 months was reported. The use of EGFR (and variants) as a target is restricted by the fact that only 60-80% of high-grade gliomas [56], according to other studies only 50-60% [34,65] of gliomas, overexpress the molecule.…”
Section: Other Targetsmentioning
confidence: 99%
See 4 more Smart Citations
“…Two phase I trials with the EGFR-specific mAb nimotuzumab labeled with 188-Re have been published [18,101] and a median overall survival of 18.7 months was reported. The use of EGFR (and variants) as a target is restricted by the fact that only 60-80% of high-grade gliomas [56], according to other studies only 50-60% [34,65] of gliomas, overexpress the molecule.…”
Section: Other Targetsmentioning
confidence: 99%
“…However, two trials compared RIT alone with RIT plus adjuvant temozolomide (TMZ): Bartolomei et al [7] The median overall survival in the first group was 17.5 months and was significantly prolonged to 25 months in the iRIT + TMZ group. Li et al [56], in a long-term phase II observational study, used systemically applied I-125-labeled anti-EGFR mAb 425 (3 cycles of 50 mCi, totaling 150 mCi), starting 4-6 weeks after completion of surgery and radiotherapy. Among the 192 patients, 132 were treated with I-125-mAb 425 alone and 60 at a later time were treated with I-125-mAb 425 plus temozolomide.…”
Section: Other Targetsmentioning
confidence: 99%
See 3 more Smart Citations